ライフサイエンスコーパス: embolism

1 PCC related (ischaemic stroke and pulmonary embolism).

2 veins, one peripheral vein and one pulmonary embolism).

3 in thrombosis in the arm or leg or pulmonary embolism.

4 preceded root shrinkage or significant xylem embolism.

5 uses on the included patients with pulmonary embolism.

6 re disease, have increased risk of pulmonary embolism.

7 not reduce the risk of subsequent pulmonary embolism.

8 3319 patients had pulmonary embolism.

9 y have unique therapeutic value in pulmonary embolism.

10 ify and treat patients at risk for pulmonary embolism.

11 arterial system is referred to as pulmonary embolism.

12 y; however, there is a risk of pulmonary gas embolism.

13 rought, such as wilting and substantial stem embolism.

14 xylem dysfunction-and xylem vulnerability to embolism.

15 mortality due to related stroke and systemic embolism.

16 oss of stem hydraulic conductivity via xylem embolism.

17 ke, transient ischemic attack, or peripheral embolism.

18 aphy was performed to evaluate for pulmonary embolism.

19 eep vein thrombosis of the leg and pulmonary embolism.

20 e pulmonary trunk to investigate a pulmonary embolism.

21 stroke/transient ischemic attack or systemic embolism.

22 tions, venous thromboembolism, and pulmonary embolism.

23 tment for deep vein thrombosis and pulmonary embolism.

24 icant neurological injury resulting from air embolism.

25 h certain causes of arrest such as pulmonary embolism.

26 ion of PH after exclusion of acute pulmonary embolism.

27 ice from prostasome-induced lethal pulmonary embolism.

28 n lead to deep-vein thrombosis and pulmonary embolism.

29 omboembolic events with or without pulmonary embolism.

30 ence of an effect of statin use on pulmonary embolism.

31 e migration, caval penetration, or pulmonary embolism.

32 t ventricular dysfunction in acute pulmonary embolism.

33 e risk of having an ischemic stroke/systemic embolism.

34 n/outpatients diagnosed with acute pulmonary embolism.

35 roke, transient ischemic attack, or systemic embolism.

36 e examined in a humanized model of pulmonary embolism.

37 hodological limitations in the evaluation of embolism.

38 on is particularly associated with pulmonary embolism.

39 physicians in patients with acute pulmonary embolism.

40 nd function in patients with acute pulmonary embolism.

41 igher vulnerability to drought-induced xylem embolism.

42 t ventricular dysfunction in acute pulmonary embolism.

43 l size at which bubbles would expand to form embolisms.

44 d a very low rate of stroke (0%), peripheral embolism (0%), and severe hemorrhage (n = 1, 3.7%).

45 y thrombosis (0.77% versus 0.96%), pulmonary embolism (0.38% versus 0.96%), or urgent surgery (1.15%

46 echanism (spontaneous dissection, vasospasm, embolism; 1.5% women, 0.2% men); and class 5, undetermin

47 The rates of pulmonary embolism (12.1% versus 7.8%; P=0.02), intracranial hemor

48 on suffered 2-fold higher rates of pulmonary embolism (2.6% versus 1.3%; rate ratio [RR] 2.0; 95% CI

49 or probably related to treatment (pulmonary embolism [200 mg/day], respiratory failure [120 mg/day],

50 fatigue (50 [6%] vs 14 [2%]), and pulmonary embolism (40 [5%] vs 27 [4%]).

51 areness is substantially lower for pulmonary embolism (54%) and deep-vein thrombosis (44%) than heart

52 between the groups, except for thrombosis or embolism--a known side-effect of tamoxifen-for which the

53 Cardiac embolism accounts for an increasing proportion of ischem

54 risk of stroke or non-central nervous system embolism (adjusted hazard ratio, 1.02 for >/= 10 versus

55 isk for stroke or non-central nervous system embolism (adjusted hazard ratio, 1.39; 95% CI, 1.05-1.84

56 dividual venation network, susceptibility to embolism always increased proportionally with the size o

57 The prevalence of pulmonary embolism among patients hospitalized for syncope is not

58 18)F-FDG PET/CT identified 8 cases of septic embolism and 3 of colorectal cancer in patients with a f

59 ow-up), the rate of ischemic stroke/systemic embolism and all-cause mortality (per 100 person-years)

60 ted hazard ratio of ischemic stroke/systemic embolism and all-cause mortality was 0.55 (95% confidenc

61 mbolism (which comprised events of pulmonary embolism and deep-vein thrombosis) was more common in th

62 ct the xylem from tensions that would induce embolism and disruption of water transport under mild to

63 s thromboembolism in patients with pulmonary embolism and evidence of right ventricular dysfunction.

64 dose-limiting toxicities (grade 2 pulmonary embolism and grade 4 hypocellular marrow) occurred durin

65 The role of embolism and hemodynamic disturbances caused by carotid

66 Annualized event rates of stroke or systemic embolism and major bleeding and hazard ratios (HRs) and

67 ion have a higher risk of stroke or systemic embolism and major bleeding but show consistent benefits

68 n vs warfarin on rates of stroke or systemic embolism and major bleeding were consistent in patients

69 ow pretest clinical probability of pulmonary embolism and negative d-dimer assay.

70 e at significantly greater risk of pulmonary embolism and required longer hospital stay.

71 (OR = 1.64; P = 2.5 x 10(-3)), and arterial embolism and thrombosis (OR = 1.88; P = 4.2 x 10(-3)).

72 available, the rapid diagnosis of pulmonary embolism and use of thrombolytics during cardiopulmonary

73 , i.e., stroke (ischemic stroke and systemic embolism) and major bleeding in patients treated in rout

74 her the primary efficacy (stroke or systemic embolism) and safety (major bleeding and nonmajor clinic

75 as bubble formation within the blood stream (embolism) and tissues leading to organ injury, impairmen

76 sease, invasive breast cancer, and pulmonary embolism), and raloxifene (venous thromboembolism).

77 tcomes, stroke or non-central nervous system embolism, and all-cause mortality.

78 Efficacy outcomes were stroke or systemic embolism, and all-cause mortality.

79 old patient in the placebo group died of fat embolism, and another patient in the placebo group withd

80 warfarin) for prevention of stroke, systemic embolism, and cardiovascular death in nonvalvular atrial

81 warfarin for prevention of stroke, systemic embolism, and cardiovascular death in patients with nonv

82 ke/transient ischemic attack, prior systemic embolism, and congestive heart failure were associated w

83 risk factors), and unprovoked VTE, pulmonary embolism, and deep-vein thrombosis.

84 r failure, venous thromboembolism, pulmonary embolism, and operative complications.

85 infarction, deep vein thrombosis, pulmonary embolism, and pneumonia).

86 Of these, 3 events-syncope, pulmonary embolism, and serum creatinine increase-in 3 patients we

87 monary surgery, those who suffered pulmonary embolism, and those in the IGCCCG poor prognostic group.

88 rial fibrillation, cardiac arrest, pulmonary embolism, and/or stroke).

89 Deep vein thrombosis (DVT) and pulmonary embolism are collectively known as venous thromboembolis

90 lity of different species to drought-induced embolism are indirect and invasive, increasing the possi

91 e, transient ischemic attacks, and pulmonary embolism are major causes of morbidity and mortality wor

92 nduits were embolized, and substantial xylem embolism arose only under severe dehydration.

93 d patients with acute, symptomatic pulmonary embolism associated with lower-limb vein thrombosis and

94 We compared the rates of stroke/systemic embolism at 1 year according to diabetes status (no diab

95 nificantly increased risk of stroke/systemic embolism at 1 year versus either no diabetes (5.2% vs. 1

96 n thrombosis or non-fatal or fatal pulmonary embolism at 12 months.

97 the risk of symptomatic recurrent pulmonary embolism at 3 months.

98 outcome was symptomatic recurrent pulmonary embolism at 3 months.

99 Secondary outcomes were recurrent pulmonary embolism at 6 months, symptomatic deep vein thrombosis,

100 absence of deep vein thrombosis or pulmonary embolism at the time of IVC filter placement.

101 hod that allows the initiation and spread of embolism bubbles in the leaf network to be visualized.

102 includes deep vein thrombosis and pulmonary embolism), but the evidence is uncertain.

103 which hydraulic failure from drought-induced embolism can lead to organ or whole plant death.

104 When pulmonary embolism coexists with a patent foramen ovale, increased

105 when cardiac arrest was caused by pulmonary embolism compared with hypoxia and primary arrhythmia.

106 oxaban had a reduction in stroke or systemic embolism compared with those taking warfarin (1.54 versu

107 ated with lower rates of stroke and systemic embolism compared with warfarin, without an increase in

108 tion from cardiac arrest caused by pulmonary embolism, compared with hypoxia and primary arrhythmia.

109 boses and deep-vein thrombosis and pulmonary embolism comprise venous thromboembolism.

110 atic VTE (deep vein thrombosis and pulmonary embolism, confirmed by duplex ultrasonography and chest

111 n is a critical determinant of the spread of embolism damage to leaves during drought.

112 Rates of ischemic stroke/systemic embolism, death, and bleeding.

113 Finally, complications (pulmonary embolism, deep vein thrombosis, acute respiratory distre

114 heparin for preventing mortality, pulmonary embolism, deep venous thrombosis, bleeding outcomes, or

115 In our case, we found both pulmonary embolism due to DVT and paradoxical embolism due to exis

116 ulmonary embolism due to DVT and paradoxical embolism due to existing patent foramen ovale.

117 I], 1.16-1.5) but similar stroke or systemic embolism event rates (HR, 1.09; 95% CI, 0.88-1.33).

118 is effective for the prevention of pulmonary embolism for at least 5 weeks after placement in swine.

119 mography pulmonary angiography for pulmonary embolism) for those with a high pretest probability.

120 t the entire growing season, suggesting that embolism formation and repair are not routine and mainly

121 t the safety of xylem (its ability to resist embolism formation and spread) should trade off against

122 (i.e. vessel refilling) by water influx and embolism formation by water efflux were directly linked

123 rotomography (microCT) to directly visualize embolism formation in the xylem of living, intact plants

124 gative water potentials without considerable embolism formation in their xylem conduits during drough

125 Only under increased drought stress was embolism formation observed in the root xylem, and it ap

126 d with H2O showed no refilling and increased embolism formation.

127 s possible without root pressure, and if the embolism formation/removal affects vessel functional sta

128 Gas embolisms formed during drought can disrupt long-distanc

129 networks under tension and is vulnerable to embolism-forming cavitations, which cut off water supply

130 d to be related to study drug were pulmonary embolism (four patients; 8%), vomiting (four; 8%), dehyd

131 or bleeding, from 0.2% to 0.9% for pulmonary embolism, from 0.1% to 0.7% for periprocedural mortality

132 an in trees due to the formation of frequent embolisms (gas bubbles), which could be removed by the o

133 arrest with contributing reason of pulmonary embolism (grade 4, suspected to be study drug related) 4

134 ution of low-risk-factor patients in the non-embolism group, and the distribution of high-risk-factor

135 ention of deep-vein thrombosis and pulmonary embolism has been shown in phase 3 trials.

136 ombosis (DVT) and its complication pulmonary embolism have high morbidity reducing quality of life an

137 ients had higher rates of stroke or systemic embolism (HR, 1.47; 95% CI, 1.20-1.81) and major bleedin

138 ore effective (outcome of stroke or systemic embolism: HR, 0.78; 95% CI, 0.67-0.91; vascular death: H

139 53; 95% CI, 1.17-2.01 for stroke or systemic embolism; HR, 1.56; 95% CI, 1.27-1.93 for major bleeding

140 rought tolerance traits (xylem resistance to embolism, hydraulic safety margin, wood density) at the

141 igned to cardiac arrest induced by pulmonary embolism, hypoxia, or primary arrhythmia.

142 ding to serious sequelae (eg, amniotic fluid embolism, hysterectomy), complications requiring intensi

143 Pulmonary surgery, pulmonary embolism, IGCCCG poor prognosis, and smoking influenced

144 monary infection in 80 (6.5%), and pulmonary embolism in 47 (3.8%) patients.

145 the control group), of which one-a pulmonary embolism in a 64-year-old male patient after 11 months o

146 embolism, deep vein thrombosis, or pulmonary embolism in adults were included, as were intervention s

147 performed a systematic workup for pulmonary embolism in patients admitted to 11 hospitals in Italy f

148 d the rate of bleeding, stroke, and arterial embolism in patients who started dabigatran, rivaroxaban

149 th warfarin (n = 8657) on stroke or systemic embolism in patients with 1 dose-reduction criterion (HR

150 in for the prevention of stroke and systemic embolism in patients with atrial fibrillation and for th

151 ferior for prevention of stroke and systemic embolism in patients with atrial fibrillation and is ass

152 herapy for the prevention of stroke/systemic embolism in patients with atrial fibrillation.

153 herapy alone for the secondary prevention of embolism in patients with patent foramen ovale (PFO) and

154 of (1) the vulnerability to drought-induced embolism in perennial and annual organs and (2) the abil

155 to examine risk factors associated with gas embolism in sea turtles captured in trawls and gillnets.

156 tended to attribute the decline of Kleaf to embolism in the leaf vein xylem.

157 stomatal closure preceded the appearance of embolism in the leaves and the stem by several days.

158 As a result, embolism in the stem was minimal even when drought led t

159 tention to a diagnostic workup for pulmonary embolism in these patients.

160 nts died from adverse events; one (pulmonary embolism in treatment group A) was possibly related to t

161 nfidence interval, 1.80-2.05), and pulmonary embolism (incidence rate ratio, 1.80; 95% confidence int

162 w airway pressure, the risk of pulmonary gas embolism increases when PPP is higher than CVP.

163 significantly overestimated vulnerability to embolism, indicating that caution should be used when ap

164 ng approval of rivaroxaban for the pulmonary embolism indication, patients with deep-vein thrombosis

165 d with thrombolytic therapy during pulmonary embolism-induced cardiopulmonary arrest and discuss the

166 their vein supply network to protect against embolism-induced failure has enormous ecological and evo

167 Examining embolism-induced failure of architecturally diverse leaf

168 tance (Kx ) during dehydration was driven by embolism initiating in petioles and midribs across all s

169 reduced risk for ischemic stroke or systemic embolism, intracranial hemorrhage, and all-cause mortali

170 garding risk for ischemic stroke or systemic embolism, intracranial hemorrhage, myocardial infarction

171 lysis of 143 patients suspected of pulmonary embolism investigated with 3 different scanners (16 to 8

172 Xylem vulnerability to embolism is emerging as a major factor in drought-induce

173 gnosis of deep-vein thrombosis and pulmonary embolism is nonspecific, integrated diagnostic approache

174 Hydraulic failure induced by xylem embolism is one of the primary mechanisms of plant dieba

175 fter a first episode of unprovoked pulmonary embolism is uncertain.

176 (DVT) with its major complication, pulmonary embolism, is a global health problem.

177 sion, a rare complication of acute pulmonary embolism, is characterized by fibrothrombotic obstructio

178 bin generation and protection from pulmonary embolism, leading to prolonged survival.

179 The risks of stroke or systemic embolism, major bleeding, and mortality were higher in p

180 of myocardial infarction, stroke or systemic embolism, major bleeding, cause-specific hospitalization

181 of myocardial infarction, stroke or systemic embolism, major bleeding, hospitalization, or death with

182 Rates of stroke or systemic embolism, myocardial infarction, and bleeding were also

183 -up: 0.99 years) included stroke or systemic embolism, myocardial infarction, major bleeding (Interna

184 BAT in one [3%] patient each were pulmonary embolism, myocardial infarction, urinary obstruction, ga

185 veness end point of ischemic stroke/systemic embolism, no significant differences of the NOACs compar

186 a serious adverse event of grade 4 pulmonary embolism occurred in one patient.

187 No pulmonary embolism occurred.

188 Pulmonary embolism often causes cardiac arrest.

189 T can be used to assess the vulnerability to embolism on intact plants by direct visualization.

190 nous thromboembolism manifested as pulmonary embolism or deep vein thrombosis.

191 shown) and revealed no evidence of pulmonary embolism or lower extremity thrombus.

192 composite, and death unrelated to pulmonary embolism or major bleeding, at 18 and 42 months.

193 oring novel oral anticoagulants for systemic embolism (OR, 0.84; 95% CI, 0.72-0.97; P=0.01), all-caus

194 mption, acute pericardial disease, pulmonary embolism, or other acute pulmonary disease).

195 in those with a history of stroke, systemic embolism, or transient ischemic attack was 39.4%/y versu

196 e arterial thromboembolism (stroke, systemic embolism, or transient ischemic attack) and major bleedi

197 stomatal closure precedes the occurrence of embolism, others believe that the two are contemporaneou

198 embolism, deep vein thrombosis, or pulmonary embolism outcomes.

199 sed the risk for ischemic stroke or systemic embolism (p = 0.0004 and p = 0.0006, respectively), intr

200 ary hypertension (1B), symptomatic pulmonary embolism (PE) (1C), right ventricular (RV) infarct (1C),

201 LRnon-neonates, respectively), and pulmonary embolism (PE) (P < .001; 19.6% and 3.2% in Non-LR and LR

202 ients who were suspected of having pulmonary embolism (PE) and who underwent CT pulmonary angiography

203 Pulmonary embolism (PE) can be a severe disease and is difficult t

204 While pulmonary embolism (PE) causes approximately 100 000-180 000 death

205 ocessing (NLP) model in extracting pulmonary embolism (PE) findings from thoracic computed tomography

206 lear whether mortality after acute pulmonary embolism (PE) has decreased over time.

207 the treatment and outcome of acute pulmonary embolism (PE) have remained relatively unchanged over th

208 ifferent diagnostic strategies for pulmonary embolism (PE) in patient subgroups is unclear.

209 Pulmonary embolism (PE) is a serious and prevalent cause of vascul

210 ffect of thrombolytic treatment of pulmonary embolism (PE) is unknown.

211 na cava filter (VCF) placement for pulmonary embolism (PE) prophylaxis in trauma is controversial.

212 Pulmonary embolism (PE) remains a major contributor to global dise

213 y result in proximal thrombosis or pulmonary embolism (PE).

214 are widely used for prevention of pulmonary embolism (PE).

215 ters (IVCFs) may prevent recurrent pulmonary embolism (PE).

216 ing deep vein thrombosis (DVT) and pulmonary embolism (PE).

217 s with hemodynamically significant pulmonary embolism, physiological fibrinolysis fails to dissolve t

218 ribution of high-risk-factor patients in the embolism-positive group was statistically significantly

219 Stroke or systemic embolism (primary outcome), major bleeding (safety outco

220 ymptomatic deep-vein thrombosis or pulmonary embolism, progression or recurrence of superficial vein-

221 ymptomatic deep-vein thrombosis or pulmonary embolism, progression or recurrence of superficial vein-

222 ese cryptogenic strokes arise from a distant embolism rather than in situ cerebrovascular disease, le

223 findings suggest that grapevine avoids xylem embolism rather than tolerates it.

224 Complications of CRT include pulmonary embolism, recurrent deep venous thrombosis, loss of cent

225 ntact angles indicated that the processes of embolism removal (i.e. vessel refilling) by water influx

226 Our data show that embolism removal in excised stems was driven by water dr

227 Embolism removal is critical for restoring hydraulic pat

228 Despite evidence suggesting that embolism removal is linked to the presence of vessel-ass

229 y on excised grapevine stems to determine if embolism removal is possible without root pressure, and

230 Much of our understanding of embolism removal remains theoretical as a consequence of

231 and temporal dynamics of the final stages of embolism removal.

232 tal myocardial infarction, stroke, pulmonary embolism, renal failure, or bowel infarction) within 30

233 tal myocardial infarction, stroke, pulmonary embolism, renal failure, or bowel infarction) within 30

234 situation would necessitate daily cycles of embolism repair to restore hydraulic function.

235 In this study, embolism repair was investigated in relation to xylem st

236 or all 23 species in this group, we measured embolism resistance (P50 ), xylem specific hydraulic con

237 unctions allowed Callitris to evolve extreme embolism resistance and diversify into xeric environment

238 Embolism resistance varied widely across the Callitris c

239 and therapeutic plan is through a Pulmonary Embolism Response Team, which combines expertise from in

240 In patients with pulmonary embolism, right ventricular dysfunction is associated wi

241 rior to the event and 167 (88.4%) had a high embolism risk score, of whom 139 (83.2%) were also at lo

242 bability of PE who do not meet all Pulmonary Embolism Rule-Out Criteria.

243 well-managed warfarin for stroke or systemic embolism (S/SE) prevention and reduced bleeding in patie

244 rfarin for prevention of stroke and systemic embolism (SE) in AF.

245 ment (LAE) is a predictor of stroke/systemic embolism (SE) in atrial fibrillation (AF) patients.

246 osite coprimary endpoint of stroke, systemic embolism (SE), or cardiovascular/unexplained death did n

247 ventilation, respiratory failure, pulmonary embolism, sepsis, or death.

248 grade 3 and 4 adverse events were pulmonary embolism (seven [3%]), prolonged electrocardiogram QT (f

249 D physiological modelling to investigate how embolisms spread throughout petioles and vein orders dur

250 Anti-embolism stockings are the most widely used non-invasive

251 The pressure exerted by anti-embolism stockings decreases with use but the correct pr

252 Different brands of anti-embolism stockings exert different pressures on the same

253 ant patients are frequently fitted with anti-embolism stockings on admission to hospital, to aid bloo

254 ing ability of 2 major global brands of anti-embolism stockings over 5-8days of simulated wear (exten

255 The pressure exerted by anti-embolism stockings reduced by between 15 and 24% after 2

256 s on the pressure delivering ability of anti-embolism stockings.

257 Basal leaves were more vulnerable to xylem embolism than apical leaves and, once embolized, were sh

258 r had active cancer or concomitant pulmonary embolism than those in the standard anticoagulation grou

259 rapid refilling and compartmentalization of embolisms that occur in small vessels, while promoting h

260 ients with deep vein thrombosis or pulmonary embolism) that occurred during the patient's initial hos

261 talized patients with severe acute pulmonary embolism, the use of a retrievable inferior vena cava fi

262 (Pulmonary Embolism Thrombolysis study [PEITHO]; NCT00639743).

263 The PEITHO (Pulmonary Embolism Thrombolysis) trial was a randomized (1:1) comp

264 draulic system should be more susceptible to embolism to protect the rest of the water transport syst

265 dvanced by noninvasive techniques that allow embolisms to be viewed directly in the vascular system.

266 in K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study.

267 in K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation trial) differed am

268 in K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial.

269 f eight), diarrhea (two of eight), pulmonary embolism (two of eight), pulmonary hypertension (one of

270 Risk stratification for acute pulmonary embolism using imaging presence of right ventricular dys

271 lyzed their vulnerability to drought-induced embolism using solutions of different gamma and estimate

272 Venous air embolism (VAE) during pars plana vitrectomy (PPV) can oc

273 udy that report all-cause stroke or systemic embolism, vascular death, myocardial infarction, major b

274 point of stroke, non-central nervous system embolism, vascular death, or myocardial infarction (adju

275 ents with deep vein thrombosis and pulmonary embolism (venous thromboembolism, VTE), biomarkers or ge

276 a, sepsis, deep venous thrombosis, pulmonary embolism, venous thromboembolism, and myocardial infarct

277 e entire cohort, the prevalence of pulmonary embolism was 17.3% (95% confidence interval, 14.2 to 20.

278 Analysis of stroke or systemic embolism was based on intention to treat.

279 Embolism was experimentally induced in excised vascular

280 Pulmonary embolism was identified in 45 of the 355 patients (12.7%

281 Among the remaining 230 patients, pulmonary embolism was identified in 97 (42.2%).

282 Pulmonary embolism was identified in nearly one of every six patie

283 Pulmonary embolism was induced by jugular vein infusion of (125)I-

284 No case of amniotic fluid embolism was observed.

285 A diagnosis of pulmonary embolism was ruled out in 330 of the 560 patients (58.9%

286 The diagnosis of pulmonary embolism was ruled out in patients who had a low pretest

287 All-cause stroke or systemic embolism was similar between both strategies (1.75 vs. 1

288 ep-vein thrombosis and concomitant pulmonary embolism were also eligible; however, those with isolate

289 owing collagen/epinephrine-induced pulmonary embolism were also observed in Dicer1-deficient animals.

290 ctors for deep vein thrombosis and pulmonary embolism were assessed.

291 ischemic stroke and ischemic stroke/systemic embolism were explored.

292 ible; however, those with isolated pulmonary embolism were not included.

293 Notably, rates of stroke/embolism were similar in patients with diabetes not rece

294 th blockages in vessel elements, whereas air embolisms were negligible.

295 or with intermediate- to high-risk pulmonary embolism, were underrepresented in the Phase III trials.

296 nalysis: 32 mm (95% CI, 29-36) for pulmonary embolism which was significantly larger than both hypoxi

297 as found between depth, risk and severity of embolism, which has not been previously demonstrated in

298 in thrombosis or acute symptomatic pulmonary embolism (with or without deep-vein thrombosis) were ass

299 imal deep vein thrombosis (DVT) or pulmonary embolism, with a life expectancy greater than 6 months a

300 ke, transient ischemic attack, and pulmonary embolism) yielded a 44% higher annual risk than if only